propafenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiarrhythmics, propafenone derivatives 2291 54063-53-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propafenone
  • propafenone hydrochloride
  • polfenon
  • (RS)-Propafenone
  • propafenone HCl
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
  • Molecular weight: 341.45
  • Formula: C21H27NO3
  • CLOGP: 3.64
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 58.56
  • ALOGS: -4.65
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.09 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 12 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1989 FDA GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atrial fibrillation 215.03 17.39 153 8218 116483 63364168
Electrocardiogram QRS complex prolonged 179.82 17.39 55 8316 5883 63474768
Drug interaction 162.11 17.39 174 8197 228957 63251694
Bradycardia 141.57 17.39 99 8272 73128 63407523
Sinus bradycardia 111.82 17.39 49 8322 14502 63466149
Arrhythmia 84.16 17.39 56 8315 38084 63442567
Completed suicide 68.52 17.39 90 8281 145583 63335068
Cardiac arrest 64.69 17.39 70 8301 92475 63388176
Toxicity to various agents 60.46 17.39 113 8258 247137 63233514
Enzyme induction 54.05 17.39 9 8362 53 63480598
Syncope 52.82 17.39 71 8300 117314 63363337
Intentional overdose 48.18 17.39 54 8317 74098 63406553
Atrioventricular block complete 45.26 17.39 22 8349 8229 63472422
Hypotension 44.88 17.39 106 8265 272498 63208153
Atrial flutter 44.60 17.39 23 8348 9749 63470902
Palpitations 44.43 17.39 64 8307 112706 63367945
Asthenia 43.68 17.39 130 8241 383474 63097177
Cardiogenic shock 43.61 17.39 28 8343 17904 63462747
Bradyarrhythmia 41.12 17.39 14 8357 2101 63478550
International normalised ratio increased 39.41 17.39 39 8332 46386 63434265
Loss of consciousness 37.98 17.39 61 8310 118060 63362591
Systolic dysfunction 36.72 17.39 12 8359 1587 63479064
Nodal arrhythmia 36.16 17.39 11 8360 1152 63479499
Generalised tonic-clonic seizure 35.65 17.39 30 8341 28986 63451665
Dizziness 34.08 17.39 129 8242 429796 63050855
Ventricular tachycardia 31.69 17.39 24 8347 19955 63460696
Electrocardiogram abnormal 29.15 17.39 17 8354 9162 63471489
Tension 28.70 17.39 12 8359 3163 63477488
Granulocytopenia 27.77 17.39 14 8357 5658 63474993
Bundle branch block left 27.64 17.39 15 8356 7044 63473607
Cardiac assistance device user 27.60 17.39 5 8366 51 63480600
Atrioventricular block first degree 27.22 17.39 15 8356 7258 63473393
Pain 26.98 17.39 35 8336 740593 62740058
Coagulation test abnormal 26.76 17.39 8 8363 790 63479861
Haemodynamic instability 26.51 17.39 16 8355 9174 63471477
Bradykinesia 25.97 17.39 13 8358 5175 63475476
Flat affect 25.86 17.39 9 8362 1441 63479210
Conduction disorder 25.76 17.39 9 8362 1458 63479193
Labelled drug-drug interaction medication error 25.57 17.39 18 8353 13381 63467270
Duplicate therapy error 24.81 17.39 5 8366 93 63480558
Suicide attempt 24.59 17.39 35 8336 60883 63419768
Product measured potency issue 24.01 17.39 5 8366 110 63480541
Atrioventricular block 23.85 17.39 14 8357 7633 63473018
Rhabdomyolysis 23.53 17.39 29 8342 43922 63436729
Psychomotor retardation 23.30 17.39 11 8360 3859 63476792
Heart rate irregular 23.15 17.39 21 8350 22400 63458251
Brugada syndrome 22.64 17.39 6 8365 382 63480269
Defect conduction intraventricular 22.62 17.39 5 8366 147 63480504
Ischaemic hepatitis 22.55 17.39 9 8362 2107 63478544
Periorbital haematoma 22.53 17.39 7 8364 787 63479864
Noninfective gingivitis 22.12 17.39 8 8363 1433 63479218
Product dispensing issue 21.86 17.39 5 8366 172 63480479
Tachycardia 21.66 17.39 48 8323 118108 63362543
Acute kidney injury 21.61 17.39 80 8291 263335 63217316
Metabolic acidosis 21.37 17.39 28 8343 45041 63435610
Overdose 21.37 17.39 47 8324 115031 63365620
N-terminal prohormone brain natriuretic peptide 21.26 17.39 4 8367 51 63480600
Diastolic dysfunction 20.59 17.39 12 8359 6459 63474192
Overweight 20.57 17.39 10 8361 3741 63476910
Brain oedema 20.22 17.39 16 8355 14179 63466472
Rhythm idioventricular 19.84 17.39 5 8366 261 63480390
Sinus arrest 19.77 17.39 8 8363 1941 63478710
pH body fluid abnormal 19.48 17.39 4 8367 82 63480569
Myocardial ischaemia 19.41 17.39 15 8356 12844 63467807
Cardioversion 19.36 17.39 7 8364 1253 63479398
Supraventricular tachycardia 18.03 17.39 15 8356 14256 63466395
Arthralgia 17.70 17.39 30 8341 569680 62910971

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged 263.33 18.25 73 5219 4821 34946818
Bradycardia 135.78 18.25 103 5189 75315 34876324
Electrocardiogram PR prolongation 105.64 18.25 25 5267 870 34950769
Atrial fibrillation 91.17 18.25 102 5190 122291 34829348
Drug interaction 73.30 18.25 126 5166 225820 34725819
Palpitations 59.70 18.25 49 5243 39937 34911702
Facial asymmetry 58.87 18.25 13 5279 330 34951309
Ventricular tachycardia 56.01 18.25 40 5252 26539 34925100
Accidental exposure to product by child 40.07 18.25 13 5279 1463 34950176
Neonatal pneumonia 39.79 18.25 8 5284 127 34951512
Atrioventricular block first degree 39.44 18.25 19 5273 6073 34945566
Neonatal hypotension 38.33 18.25 8 5284 154 34951485
Arrhythmia 35.78 18.25 35 5257 35773 34915866
Ventricular arrhythmia 35.05 18.25 17 5275 5511 34946128
Dizziness 34.48 18.25 91 5201 218430 34733209
Haematuria 32.56 18.25 39 5253 50027 34901612
Atrial flutter 31.79 18.25 23 5269 15551 34936088
Brugada syndrome 29.89 18.25 9 5283 792 34950847
Syncope 28.18 18.25 50 5242 91401 34860238
Bundle branch block right 27.45 18.25 16 5276 7500 34944139
Dry mouth 27.40 18.25 28 5264 30137 34921502
Speech disorder 25.45 18.25 25 5267 25661 34925978
Electrocardiogram QT prolonged 25.15 18.25 31 5261 40921 34910718
Nodal arrhythmia 24.92 18.25 8 5284 870 34950769
Heart rate irregular 24.89 18.25 20 5272 15787 34935852
Drug level increased 24.73 18.25 23 5269 22073 34929566
Accidental overdose 24.56 18.25 22 5270 20118 34931521
Completed suicide 24.43 18.25 49 5243 98119 34853520
Respiratory disorder neonatal 23.62 18.25 9 5283 1621 34950018
Toxicity to various agents 23.42 18.25 75 5217 200287 34751352
Hypotension 22.40 18.25 79 5213 221570 34730069
Transient ischaemic attack 22.16 18.25 24 5268 27589 34924050
Generalised tonic-clonic seizure 21.71 18.25 21 5271 21153 34930486
Ventricular asystole 21.40 18.25 5 5287 164 34951475
Sopor 20.49 18.25 16 5276 12120 34939519
Cholestatic liver injury 20.39 18.25 9 5283 2355 34949284
Sinus bradycardia 19.56 18.25 16 5276 12947 34938692
Supraventricular tachycardia 19.51 18.25 15 5277 11102 34940537
Cardiac flutter 19.09 18.25 8 5284 1845 34949794
Loss of consciousness 19.07 18.25 40 5252 82627 34869012

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged 431.01 16.03 129 12464 10704 79721091
Bradycardia 236.46 16.03 185 12408 135372 79596423
Atrial fibrillation 218.77 16.03 208 12385 197678 79534117
Drug interaction 208.77 16.03 290 12303 414893 79316902
Sinus bradycardia 106.79 16.03 60 12533 25187 79706608
Electrocardiogram PR prolongation 99.70 16.03 27 12566 1556 79730239
Arrhythmia 92.57 16.03 77 12516 61195 79670600
Ventricular tachycardia 81.19 16.03 61 12532 41874 79689921
Completed suicide 80.13 16.03 141 12452 245626 79486169
Palpitations 79.61 16.03 99 12494 126511 79605284
Toxicity to various agents 72.26 16.03 186 12407 421354 79310441
Syncope 67.79 16.03 110 12483 179339 79552456
Atrial flutter 66.87 16.03 42 12551 21583 79710212
Atrioventricular block first degree 64.81 16.03 34 12559 12457 79719338
Cardiac arrest 58.98 16.03 101 12492 171995 79559800
Generalised tonic-clonic seizure 57.78 16.03 51 12542 43859 79687936
Nodal arrhythmia 51.27 16.03 17 12576 1961 79729834
Hypotension 51.02 16.03 169 12424 440148 79291647
Dizziness 48.98 16.03 188 12405 526253 79205542
Facial asymmetry 46.96 16.03 13 12580 813 79730982
Enzyme induction 46.42 16.03 9 12584 112 79731683
Brugada syndrome 46.00 16.03 14 12579 1224 79730571
Loss of consciousness 45.43 16.03 89 12504 167854 79563941
Bundle branch block right 42.90 16.03 25 12568 11226 79720569
Intentional overdose 41.40 16.03 66 12527 105894 79625901
Retro-orbital neoplasm 39.73 16.03 7 12586 49 79731746
International normalised ratio increased 39.07 16.03 57 12536 84664 79647131
Heart rate irregular 37.20 16.03 35 12558 32644 79699151
Electrocardiogram abnormal 36.11 16.03 26 12567 16711 79715084
Conduction disorder 35.58 16.03 15 12578 3364 79728431
Neonatal pneumonia 35.45 16.03 6 12587 32 79731763
Asthenia 35.34 16.03 167 12426 511522 79220273
Neonatal hypotension 35.30 16.03 6 12587 33 79731762
Drug level increased 33.26 16.03 36 12557 39615 79692180
Haematuria 32.74 16.03 47 12546 68789 79663006
Bradyarrhythmia 32.64 16.03 15 12578 4131 79727664
Ventricular arrhythmia 32.01 16.03 19 12574 8821 79722974
Respiratory disorder neonatal 31.97 16.03 6 12587 62 79731733
Atrioventricular block complete 31.77 16.03 24 12569 16586 79715209
Electrocardiogram QT prolonged 30.86 16.03 53 12540 90333 79641462
Accidental exposure to product by child 30.85 16.03 13 12580 2913 79728882
Pain 29.45 16.03 41 12552 703761 79028034
Bundle branch block left 27.42 16.03 19 12574 11494 79720301
Presyncope 25.60 16.03 32 12561 41022 79690773
Arthralgia 25.24 16.03 32 12561 571771 79160024
Sinus arrest 25.10 16.03 12 12581 3610 79728185
Cardiogenic shock 25.07 16.03 32 12561 41882 79689913
Muscle mass 24.99 16.03 7 12586 457 79731338
Systolic dysfunction 24.57 16.03 12 12581 3783 79728012
Cardiac assistance device user 24.11 16.03 5 12588 89 79731706
Atrioventricular block 24.04 16.03 19 12574 14022 79717773
Tension 22.88 16.03 12 12581 4392 79727403
Rheumatoid arthritis 22.77 16.03 3 12590 208467 79523328
Flat affect 21.29 16.03 9 12584 2032 79729763
Coagulation test abnormal 21.25 16.03 8 12585 1337 79730458
Myocardial ischaemia 21.11 16.03 23 12570 25496 79706299
Supraventricular tachycardia 20.86 16.03 21 12572 21249 79710546
Cardio-respiratory arrest 20.72 16.03 50 12543 108460 79623335
Small for dates baby 20.36 16.03 6 12587 470 79731325
Product dispensing issue 20.09 16.03 5 12588 206 79731589
Suicide attempt 20.07 16.03 42 12551 82890 79648905
Periorbital haematoma 19.88 16.03 7 12586 967 79730828
Noninfective gingivitis 19.72 16.03 8 12585 1628 79730167
N-terminal prohormone brain natriuretic peptide 19.41 16.03 4 12589 69 79731726
Rash 19.26 16.03 39 12554 578319 79153476
Metabolic acidosis 19.05 16.03 41 12552 82488 79649307
Low birth weight baby 18.76 16.03 6 12587 617 79731178
Rhythm idioventricular 18.75 16.03 6 12587 618 79731177
Mental status changes 18.70 16.03 36 12557 66923 79664872
Haemodynamic instability 18.61 16.03 18 12575 17364 79714431
Bradykinesia 18.51 16.03 13 12580 8030 79723765
Ventricular asystole 18.38 16.03 5 12588 293 79731502
Duplicate therapy error 18.23 16.03 5 12588 302 79731493
Ischaemic stroke 17.80 16.03 24 12569 33107 79698688
Tachycardia 17.70 16.03 65 12528 177703 79554092
Overdose 17.22 16.03 66 12527 184140 79547655
Seizure 17.11 16.03 67 12526 188767 79543028
pH body fluid abnormal 17.08 16.03 4 12589 127 79731668
Transient ischaemic attack 16.81 16.03 30 12563 52665 79679130
Psychomotor retardation 16.62 16.03 11 12582 6173 79725622
Granulocytopenia 16.49 16.03 14 12579 11417 79720378
Labelled drug-drug interaction medication error 16.36 16.03 21 12572 27629 79704166
Atrial thrombosis 16.30 16.03 9 12584 3647 79728148
Cholestatic liver injury 16.29 16.03 10 12583 4931 79726864
Ischaemic hepatitis 16.28 16.03 9 12584 3655 79728140
Off label use 16.23 16.03 81 12512 907134 78824661

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01BC03 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ic
FDA EPC N0000175426 Antiarrhythmic
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
CHEBI has role CHEBI:38070 antiarrhythmic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atrial fibrillation indication 49436004 DOID:0060224
Paroxysmal supraventricular tachycardia indication 67198005
Paroxysmal atrial fibrillation indication 282825002
Paroxysmal atrial flutter indication 427665004
Life-Threatening Ventricular Tachycardia indication
Cardioversion of Atrial Fibrillation off-label use
Bronchospasm contraindication 4386001
Bundle branch block contraindication 6374002
Hyperkalemia contraindication 14140009
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Sick sinus syndrome contraindication 36083008 DOID:13884
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Structural disorder of heart contraindication 128599005
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Severe chronic obstructive pulmonary disease contraindication 313299006
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.15 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.48 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.69 DRUG MATRIX CHEMBL
Sodium channel subunit beta-1 Ion channel WOMBAT-PK
Sodium channel subunit beta-2 Ion channel WOMBAT-PK
Sodium channel subunit beta-3 Ion channel WOMBAT-PK
Sodium channel subunit beta-4 Ion channel WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.96 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.10 WOMBAT-PK
Multidrug resistance protein 1 Transporter ED50 7.06 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.52 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.03 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.73 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.24 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.70 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.06 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.60 WOMBAT-PK
Beta-3 adrenergic receptor GPCR Ki 6.50 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.83 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.34 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.60 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.48 DRUG MATRIX
Potassium channel subfamily K member 2 Ion channel IC50 5.12 CHEMBL
Potassium voltage-gated channel subfamily A member 5 Ion channel BLOCKER IC50 4.40 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 5.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.95 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.85 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.60 WOMBAT-PK
Sulfonylurea receptor 2, Kir6.2 Ion channel IC50 5.66 CHEMBL
Nuclear receptor subfamily 2 group E member 1 Nuclear hormone receptor EC50 4.33 CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 7.44 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 5.85 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.21 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.79 CHEMBL

External reference:

IDSource
4019911 VUID
N0000147996 NUI
D00640 KEGG_DRUG
34183-22-7 SECONDARY_CAS_RN
4019487 VANDF
4019911 VANDF
C0033429 UMLSCUI
CHEBI:63619 CHEBI
CHEMBL631 ChEMBL_ID
DB01182 DRUGBANK_ID
CHEMBL1201063 ChEMBL_ID
D011405 MESH_DESCRIPTOR_UI
4932 PUBCHEM_CID
2561 IUPHAR_LIGAND_ID
3312 INN_ID
68IQX3T69U UNII
203135 RXNORM
40681 MMSL
40682 MMSL
5368 MMSL
d00358 MMSL
003525 NDDF
004487 NDDF
108501006 SNOMEDCT_US
372910007 SNOMEDCT_US
96300001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0823 CAPSULE, EXTENDED RELEASE 225 mg ORAL NDA 29 sections
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0823 CAPSULE, EXTENDED RELEASE 225 mg ORAL NDA 29 sections
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0824 CAPSULE, EXTENDED RELEASE 325 mg ORAL NDA 29 sections
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0824 CAPSULE, EXTENDED RELEASE 325 mg ORAL NDA 29 sections
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0826 CAPSULE, EXTENDED RELEASE 425 mg ORAL NDA 29 sections
RYTHMOLSR HUMAN PRESCRIPTION DRUG LABEL 1 0173-0826 CAPSULE, EXTENDED RELEASE 425 mg ORAL NDA 29 sections
Propafenone HCl HUMAN PRESCRIPTION DRUG LABEL 1 0591-0582 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
Propafenone HCl HUMAN PRESCRIPTION DRUG LABEL 1 0591-0583 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2285 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2286 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2287 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5448 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5448 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5449 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5449 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5450 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5450 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0740 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0740 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0741 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0741 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0742 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0742 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-736 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-737 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-738 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 30 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-825 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 29 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-826 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 29 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-827 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 29 sections
Propafenone HUMAN PRESCRIPTION DRUG LABEL 1 21695-814 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 21 sections